[go: up one dir, main page]

WO2000057184A3 - Screening methods based on fha domains - Google Patents

Screening methods based on fha domains Download PDF

Info

Publication number
WO2000057184A3
WO2000057184A3 PCT/GB2000/001024 GB0001024W WO0057184A3 WO 2000057184 A3 WO2000057184 A3 WO 2000057184A3 GB 0001024 W GB0001024 W GB 0001024W WO 0057184 A3 WO0057184 A3 WO 0057184A3
Authority
WO
WIPO (PCT)
Prior art keywords
screening methods
methods based
fha domains
interaction
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/001024
Other languages
French (fr)
Other versions
WO2000057184A2 (en
Inventor
Stephen Philip Jackson
Daniel Durocher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kudos Pharmaceuticals Ltd
Original Assignee
Kudos Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906432.1A external-priority patent/GB9906432D0/en
Application filed by Kudos Pharmaceuticals Ltd filed Critical Kudos Pharmaceuticals Ltd
Priority to EP00912756A priority Critical patent/EP1163521A2/en
Priority to AU34407/00A priority patent/AU3440700A/en
Publication of WO2000057184A2 publication Critical patent/WO2000057184A2/en
Publication of WO2000057184A3 publication Critical patent/WO2000057184A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Assays, screening methods, peptides, mimetics, and methods of use are described which are based on the surprising discovery and characterisation of a direct interaction between the FHA1 domain of the Sacharomyces cerevisiae protein Rad53p, and phosphorylated polypeptides. This interaction is relevant to numerous cellular processes which are of interest in therapeutic contexts.
PCT/GB2000/001024 1999-03-19 2000-03-17 Screening methods based on fha domains Ceased WO2000057184A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00912756A EP1163521A2 (en) 1999-03-19 2000-03-17 Assays, methods and means
AU34407/00A AU3440700A (en) 1999-03-19 2000-03-17 Assays, methods and means

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9906432.1A GB9906432D0 (en) 1999-03-19 1999-03-19 Assays,methods and means
GB9906432.1 1999-03-19
GBGB9915075.7A GB9915075D0 (en) 1999-03-19 1999-06-28 Assays,methods and means
GB9915075.7 1999-06-28

Publications (2)

Publication Number Publication Date
WO2000057184A2 WO2000057184A2 (en) 2000-09-28
WO2000057184A3 true WO2000057184A3 (en) 2001-03-08

Family

ID=26315311

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/001024 Ceased WO2000057184A2 (en) 1999-03-19 2000-03-17 Screening methods based on fha domains

Country Status (4)

Country Link
EP (1) EP1163521A2 (en)
AU (1) AU3440700A (en)
GB (1) GB2348701B (en)
WO (1) WO2000057184A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660511B1 (en) * 2000-03-03 2003-12-09 Rigel Pharmaceuticals, Inc. Methods of screening for modulation of cell cycle
US8008035B2 (en) 2007-01-25 2011-08-30 Roche Diagnostics Operations, Inc. Enhancement of vanadium-containing phosphatase inhibitors
EP1949894B1 (en) * 2007-01-25 2016-06-29 Roche Diagnostics GmbH Enhancement of vanadium-containing phosphatase inhibitors by polyols
US10370776B2 (en) * 2013-09-25 2019-08-06 Idea Orchard, Llc Antibody like protein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763164A (en) * 1993-04-16 1998-06-09 Northwestern University Immunogenic cancer proteins and peptides and methods of use
WO1999042833A1 (en) * 1998-02-19 1999-08-26 Imperial Cancer Research Technology Limited Protein kinase c

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763164A (en) * 1993-04-16 1998-06-09 Northwestern University Immunogenic cancer proteins and peptides and methods of use
WO1999042833A1 (en) * 1998-02-19 1999-08-26 Imperial Cancer Research Technology Limited Protein kinase c

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DUROCHER D. ET AL.: "The FHA domain is a modular phosphopeptide recognition motif", MOLECULAR CELL, vol. 4, September 1999 (1999-09-01), pages 387 - 394, XP002151809 *
EMILI A.: "MEC1-dependent phosphorylation of Rad9p in response to DNA damage", MOLECULAR CELL, vol. 2, 1998, pages 183 - 189, XP002151812 *
HOFMANN K. ET AL.: "The FHA domain: a putative nuclear signalling domain found in protein kinases and transcription factors", TIBS, vol. 20, 1995, pages 347 - 349, XP002151811 *
LI J. ET AL.: "Kinase interaction domain of kinase-associated protein phosphatase, a phosphoprotein-binding domain.", PROC. NATL. ACAD. SCI. USA, vol. 96, July 1999 (1999-07-01), pages 7821 - 7826, XP002151814 *
PERICH J.W. ET AL.: "Synthesis of phosphopeptides by the Multipin method: evaluation of coupling methods for the incorporation of Fmoc-Tyr(PO3Bzl,H)-OH, Fmoc-Ser(PO3Bzl,H)-OH and Fmoc-Thr(PO3Bzl,H)-OH", LETTERS IN PEPTIDE SCIENCE, vol. 6, 1999, pages 91 - 97, XP000961751 *
SUN Z. ET AL.: "Rad53 FHA domain associated with phosphorylated Rad9 in the DNA damage checkpoint", SCIENCE, vol. 281, 10 July 1998 (1998-07-10), pages 272 - 274, XP002151810 *
VIALARD J.E. ET AL.: "The budding yeast Rad9 checkpoint protein is subjected to Mec1/Tel1-dependent hyperphosphorylation and interacts with Rad53 after DNA damage.", THE EMBO JOURNAL, vol. 17, no. 19, 1998, pages 5679 - 5688, XP002151813 *

Also Published As

Publication number Publication date
WO2000057184A2 (en) 2000-09-28
GB2348701B (en) 2001-06-20
GB2348701A (en) 2000-10-11
AU3440700A (en) 2000-10-09
GB0006533D0 (en) 2000-05-10
EP1163521A2 (en) 2001-12-19

Similar Documents

Publication Publication Date Title
AU2001286730A1 (en) An iap binding peptide or polypeptide and methods of using the same
WO2000063247A3 (en) Osteopontin-derived chemotactic and inhibitory agents and uses therefor
WO2001057198A3 (en) Methods of generating protein expression arrays and the use thereof in rapid screening
AU2002227279A1 (en) Polynucleotide and polypeptide sequences of putative transporters and ion channells
WO2001042277A3 (en) Complementary peptide ligands generated from the human genome
WO2000057184A3 (en) Screening methods based on fha domains
WO2000018909A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM)
EP1109904A4 (en) Novel molecules of the herpes virus-entry-mediator-related protein family and uses thereof
AU2002245371A1 (en) Novel molecules of the pyrin/nbs/lrr protein family and uses thereof
GB9918155D0 (en) Proteins and peptides
EP1009856A4 (en) Novel molecules of the fthma-070-related protein family and the t85-related protein family and uses thereof
AU5772299A (en) Novel molecules of the tango-93-related protein family and uses thereof
WO2001042287A3 (en) Putative human g-protein coupled receptors
EP1183268A4 (en) LAWSONIA DERIVED GENE AND RELATED OmpH POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES
WO2002094992A3 (en) Directed evolution of protein in mammalian cells
AU4397097A (en) Soluble polypeptides with activity of the ns3 serine protease of hepatitis c virus, and process for their preparation and isolation
EP1177212A4 (en) Lawsonia derived gene and related sodc polypeptides, peptides and proteins and their uses
WO2006024020A3 (en) Hcv non-structural protein mutants and uses thereof
EP1181315A4 (en) LAWSONIA DERIVED GENE AND RELATED FlgE POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES
AU2002362414A1 (en) Novel molecules of the hkid-1-related protein family and uses thereof
AU2161699A (en) Peptides and nucleic acids derived from (eisenia foetida) and the use thereof
EP1080185A4 (en) Myelin basic protein peptides and uses thereof
AU4729499A (en) Oct1p, a protein having homology to the organic and sugar transporter family of proteins, and uses thereof
AU2001259420A1 (en) Novel molecules of the nbs/lrr protein family and uses thereof
WO2002030977A3 (en) Egf motif protein, egfl6 materials and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000912756

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09936956

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000912756

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000912756

Country of ref document: EP